Accrelist Ltd. FY2026 Financial Review: A Turnaround Story Driven by Medical Aesthetics

Accrelist Ltd. has released its unaudited results for the financial year ended 31 March 2026. The Group, listed on the Catalist of the Singapore Exchange, continues its strategic transition with a focus on medical aesthetics through its A.M Aesthetics clinics and A.M Skincare businesses. Below we provide a structured analysis of the key financial metrics, business performance trends, and corporate developments based strictly on the disclosures in the financial report.

Key Financial Metrics & Performance Table

Summary of Results and Trends

• Revenue: The Group achieved S\$15.6 million in revenue for FY2026, up 11.5% from S\$14.0 million. The second half saw a robust 22.3% YoY revenue growth, mainly driven by the A.M Aesthetics medical services segment.
• Profitability: Net loss attributable to shareholders narrowed dramatically to S\$264,000 in FY2026 from S\$4.7 million in FY2025. The loss per share improved to (0.08) cents from (1.47) cents. The improvement was attributed to the turnaround of the aesthetics business and the absence of large impairments recorded last year.
• Margins: Gross profit margin increased significantly from 38.1% to 46.7%, reflecting better cost controls and higher revenue from the core AMS business.
• Expenses: Marketing & distribution and administrative expenses were well contained, with a notable reduction in marketing spend (-44.5% YoY) and lower administrative costs due to prior year one-off items.
• Dividends: No dividend was declared for FY2026 as the Group aims to conserve cash for future investments.
• Working Capital: The Group ended with a negative working capital of S\$0.4 million, due mainly to cash outflows for investments and debt repayment. Nevertheless, management expects cash flows to improve, given the positive operating cash flow and the cash-generative nature of the medical aesthetics business.

Corporate Actions & Other Notable Events

• Business Restructuring: The Group completed the sale of its mechanical business unit, MBU-WTE, in March 2025. This segment now only contributes as an associate, reducing operational drag.
• Expansion and Investments: Accrelist continued to expand its aesthetics clinic network and has incorporated a subsidiary in Hainan, China, to tap into regional growth opportunities. It also increased its stake in Mclean Technologies Berhad, now holding 26.91%.
• Share Issuance: 1,415,000 new shares were issued under the Accrelist PSP 2023 for director remuneration, with total potential dilution from outstanding share awards at 1.2% of share capital.
• Related-Party Transactions: A S\$378,000 management fee was received from Jubilee Industries Holdings, a related entity.

Chairman’s Statement

“Business for the Group’s AMS segment has remained relatively consistent. This is supported by resilient demand with favourable long-term prospects. Amidst an ageing population with rising affluence, the growing acceptance and accessibility of minimally invasive procedures has also opened new opportunities as more younger customers and men also begin to seek aesthetic treatments. This situation has resulted in more aesthetic clinics being set up leading to stiffer competition.

In Singapore, the Group continues to position A.M Aesthetics as one of the market leaders while pursuing network expansion. In addition, other existing clinics have also been expanded to serve more customers.

Beyond Singapore, A.M Aesthetics continues to seek growth opportunities across the region. The Group’s wholly-owned subsidiary, Accrelist Medical Aesthetics (BM) Pte. Ltd., has incorporated a company in the People’s Republic of China (“PRC”), Accrelist Medical Aesthetics (Hainan) Co., Ltd., for the purpose of expanding its medical aesthetics business in the PRC. We will continue to expand regionally to broaden the Group’s AMS revenue stream beyond Singapore, with a focus on tapping into new growth opportunities in the PRC.”

Tone: The statement is cautiously optimistic, focusing on market growth opportunities while acknowledging increased competition and the need for prudent expansion.

Exceptional Items and One-Offs

• FY2025 saw impairment losses and write-offs totalling S\$3.1 million, which did not recur in FY2026, contributing to the improved bottom line.
• No asset revaluations or delayed recognitions were noted.

Divestments, Fundraising, and Corporate Actions

• MBU-WTE divested in March 2025 – reducing group risk and operating losses.
• Share placement for directors and key management via the Performance Share Plan (Accrelist PSP 2023).
• No new debt placements, major fundraising, or IPOs in the period.

Outlook and Risks

• The medical aesthetics market remains robust with long-term tailwinds, though competition is intensifying.
• Regional expansion in China and Malaysia is underway, but execution risk remains.
• The Group’s focus on conserving cash (no dividend payout) reflects a prudent stance given the recent negative working capital.
• The performance of associate Mclean Technologies Berhad is a positive driver, with the investment now profitable and market value above the Group’s cost.

Conclusion & Investor Recommendations

Overall Assessment: Accrelist delivered a strong turnaround in FY2026, with robust revenue growth, a dramatic reduction in losses, and a successful focus on its core medical aesthetics operations. While the balance sheet remains tight with negative working capital, improving cash flows and a more focused business model support a cautiously optimistic outlook.

• If you currently hold Accrelist shares: Consider holding your position. The company has shown credible operational improvements and is positioned for growth in the medical aesthetics sector. However, monitor working capital and execution on regional expansion closely.
• If you do not currently hold Accrelist shares: Consider waiting for further evidence of sustained profitability and improved working capital before initiating a position. The growth trajectory is promising, but risks remain, especially in cash flow management and competitive intensity.

Disclaimer: This analysis is for informational purposes only and is based solely on data provided in the company’s official financial report. It does not constitute investment advice. Please conduct your own due diligence and consider your risk tolerance before making investment decisions.

雅科励时（Accrelist Ltd.）2026财年财报分析：医美业务驱动的转型故事

雅科励时（Accrelist Ltd.）公布了截至2026年3月31日的未经审计财年业绩。集团继续专注于医美业务，通过A.M Aesthetics诊所以及A.M Skincare品牌推动战略转型。以下是基于财报数据的核心财务指标、业务表现趋势及公司动态分析。

主要财务指标及业绩对比表

业绩与趋势总结

• 收入： 2026财年集团收入达1,564万新元，同比增长11.5%。下半年收入同比增长22.3%，主要由医美服务（A.M Aesthetics）拉动。
• 盈利能力： 归属股东净亏损大幅收窄至26.4万新元，较上年同期大幅改善。每股亏损亦明显收窄。
• 毛利率： 集团整体毛利率由38.1%提升至46.7%，显示核心医美业务增长及成本管控成效。
• 费用： 营销及行政费用显著下降，尤其营销费用同比减少44.5%。
• 分红： 2026财年未派息，集团选择保留现金以支持未来投资。
• 营运资金： 期末净营运资金为负40万新元，主因投资与偿债所致，但管理层预计现金流将持续改善。

公司动作及重要事项

• 业务重组： 2025年3月完成机械业务（MBU-WTE）出售，减少拖累。
• 扩张与投资： 持续拓展医美诊所网络，并在中国海南设立子公司，开拓区域增长机会。持有Mclean Technologies Berhad 26.91%股权。
• 股份发行： 根据2023年业绩股权计划发放141.5万新股，稀释潜力1.2%。
• 关联交易： 向Jubilee Industries Holdings收取38万新元管理费。

董事长声明

“集团医美业务表现保持稳定，受益于强劲的长期需求。随着人口老龄化和富裕程度上升，微创医美的接受度和可及性提升，吸引更多年轻及男性客户。市场竞争加剧，集团继续巩固A.M Aesthetics市场领导地位并拓展区域版图。我们将继续在中国等地扩张，推动集团医美收入多元化。”

解读：声明整体基调积极，强调市场机遇与扩张，但亦坦承竞争加剧。

特殊/一次性项目

• 2025财年产生310万新元减值及坏账，一次性负面影响在2026财年未再发生，推动业绩改善。

剥离、集资与公司行动

• 机械业务MBU-WTE已剥离，减轻经营负担。
• 实施绩效股权计划（Accrelist PSP 2023），用于高管激励。
• 期间无新债券、重大集资或IPO。

展望与风险

• 医美市场长期向好但竞争激烈。
• 区域扩展（中国、马来西亚）进行中，执行风险需关注。
• 集团保守现金策略（不派息）反映稳健态度，营运资金待改善。
• Mclean Technologies Berhad投资盈利，市值高于成本，有助支撑集团表现。

结论与投资建议

总体评价： 雅科励时2026财年实现强劲业绩反转，收入增长、亏损大幅收窄，医美主业表现突出。尽管资产负债表承压，但营运现金流改善、业务聚焦，支持对未来持谨慎乐观态度。

• 已持有股份者： 建议继续持有。公司运营持续改善，医美市场增长确定性高。但需密切关注营运资金与区域扩展执行情况。
• 未持有股份者： 建议观望，待公司盈利能力和营运资金持续改善后再考虑建仓。增长前景可期，但现金流与竞争风险仍存。

免责声明：本分析仅基于公司官方财报数据，不构成投资建议。投资前请结合自身风险承受能力，进行充分尽职调查。

View Accrelist Ltd Historical chart here